How These Biotech Stocks are Faring? -- Idera Pharma, BioTime, RXi Pharma, and Tenax Therapeutics

Wednesday, May 24, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 24, 2017 /PRNewswire/ --

This morning, presents for scanning Idera Pharmaceuticals

Inc. (NASDAQ: IDRA), BioTime Inc. (NYSE MKT: BTX), RXi Pharmaceuticals Corp. (NASDAQ: RXII), and Tenax Therapeutics Inc. (NASDAQ: TENX). These stocks belong to the Biotech industry, which focuses on novel drug development and clinical research aimed
at treating diseases and medical conditions. Register now and get full and free access to our downloadable research reports on these stocks at:

Idera Pharma  

On Tuesday, shares in Cambridge, Massachusetts-based Idera Pharmaceuticals Inc. recorded a trading volume of 557,164 shares. The stock ended at $1.71, declining 0.58% from the last trading session. The Company's shares have gained 1.79% over the previous three months and 14.00% on an YTD basis. The stock is trading below its 200-day moving average by 9.88%. Furthermore, shares of Idera Pharma, which focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the US, have a Relative Strength Index (RSI) of 28.54.

On April 25th, 2017, research firm Robert W. Baird initiated an 'Outperform' rating on the Company's stock, with a target price of $5 per share.

On May 04th, 2017, Idera Pharmaceuticals reported its financial and operational results for Q1 ended March 31st, 2017. Net loss applicable to common stockholders for Q1 2017 was $15.1 million; R&D expenses totaled $11.5 million; and general and administrative expense was $4.1 million. Additionally, cash, cash equivalents and investments totaled $91.3 million, as of March 31st, 2017. Access our complete research report on IDRA for free at:


Alameda, California-based BioTime Inc.'s stock finished yesterday's session 1.21% higher at $3.34. A total volume of 514,656 shares was traded, which was above their three months average volume of 348,520 shares. The Company's shares have gained 4.37% in the last one month. The stock is trading above its 50-day and 200-day moving averages by 3.05% and 0.18%, respectively. Furthermore, shares of BioTime, which focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies, have an RSI of 58.08.

On May 11th, 2017, BioTime announced that a poster related to the Company's retinal restoration technology was presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology in Baltimore, Maryland on that day. BioTime scientists have grown full-thickness, 3-D retinal tissue using the Company's proprietary pluripotent cellular platform. This tissue contains all the cell types that comprise the human retina, including RPE cells, photoreceptors and ganglion cells. The complimentary research report on BTX can be downloaded at:

RXi Pharma  

At the close of trading on Tuesday, shares in Marlborough, Massachusetts headquartered RXi Pharmaceuticals Corp. rose 0.86%, ending the day at $0.58. The stock recorded a trading volume of 62,019 shares. The Company's shares are trading 15.75% below their 50-day moving average. Moreover, shares of RXi Pharma, which focuses on developing therapeutics for unmet medical needs, have an RSI of 45.74.

On May 23rd, 2017, RXi Pharmaceuticals announced that Dr. Alexey Eliseev, the Company's Chief Business Officer, will present at the 3rd Annual Immuno-Oncology BD&L and Investment Forum. This forum will bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. The meeting will take place on June 02nd, 2017 at the Hyatt Chicago Magnificent Mile Hotel in Illinois. Register for free on and get access to the latest PDF format report on RXII at:

Tenax Therapeutics  

Morrisville, North Carolina headquartered Tenax Therapeutics Inc.'s shares ended the day 0.12% lower at $0.51 with a total trading volume of 154,128 shares. The stock has gained 9.91% in the last month. The Company's shares are trading 1.03% below their 50-day moving average. Additionally, shares of Tenax Therapeutics, which focuses on the identification, development, and commercialization of a portfolio of products for the critical care market in the US and Canada, have an RSI of 54.85.

On May 16th, 2017, Tenax Therapeutics announced that the Company met with the FDA on May 10th, 2017, to review additional data analyses from the recently completed Phase 3 LEVO-CTS clinical study of levosimendan in cardiac surgery patients at risk of LCOS. The discussion with the FDA built on previously presented primary data analyses of the LEVO-CTS trial that identified a significant interaction in levosimendan's effectiveness across surgery types enrolled in the study.

On May 18th, 2017, research firm Ladenburg Thalmann upgraded the Company's stock rating from 'Neutral' to 'Buy'. Download your free research report on TENX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store